Physician profile
Michael P Roth
NPI 1548418197
$3,399.34
in general payments reported to CMS, 2019-2025
27 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $163 · 2021: $375 · 2022: $327 · 2023: $531 · 2024: $852 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.58 |
| Education | $180.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $645.71 | 2020-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $547.37 | 2019-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.41 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $272.15 | 2022-2025 | Axios, Acquire, Wallflex Duodenal |
| Takeda Pharmaceuticals U.S.A., INC. | $271.03 | 2019-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $180.57 | 2024 | |
| Gilead Sciences, INC. | $159.15 | 2020-2024 | |
| Madrigal Pharmaceuticals | $127.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $85.61 | 2021-2025 | Uplizna |
| Olympus America INC. | $84.02 | 2019-2020 | |
| Genzyme Corporation | $82.50 | 2023-2025 | |
| Lilly USA, LLC | $81.53 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $67.94 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $65.71 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $57.95 | 2019-2024 | Sucraid, Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.63 | 2025 | |
| Celltrion USA INC. | $31.83 | 2025 | Vegzelma |
| Celgene Corporation | $31.36 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Ardelyx, INC. | $19.09 | 2024 | Ibsrela |
| Organon LLC | $17.51 | 2024 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Medtronic, INC. | $13.11 | 2022 | |
| Braintree Laboratories, INC. | $12.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.65 | 2025 | Voquezna |
| Micro-Tech Endoscopy USA, INC. | $5.15 | 2024 | Abc Balloons |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.